Cargando…

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD

BACKGROUND: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however, sometimes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puhan, Milo A., Yu, Tsung, Boyd, Cynthia M., ter Riet, Gerben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490602/ https://www.ncbi.nlm.nih.gov/pubmed/26137986 http://dx.doi.org/10.1186/s12916-015-0398-0

Ejemplares similares

Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer
por: Puhan, Milo A., et al.
Publicado: (2015)

A framework for organizing and selecting quantitative approaches for benefit-harm assessment
por: Puhan, Milo A, et al.
Publicado: (2012)

Simple functional performance tests and mortality in COPD
por: Puhan, Milo A., et al.
Publicado: (2013)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

Prediction of long-term clinical outcomes using simple functional exercise performance tests in patients with COPD: a 5-year prospective cohort study
por: Crook, Sarah, et al.
Publicado: (2017)

Characteristics of Dutch and Swiss primary care COPD patients – baseline data of the ICE COLD ERIC study
por: Siebeling, Lara, et al.
Publicado: (2011)

Physical activity and risk of comorbidities in patients with chronic obstructive pulmonary disease: a cohort study
por: Yu, Tsung, et al.
Publicado: (2017)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

Prediction of COPD-specific health-related quality of life in primary care COPD patients: a prospective cohort study
por: Siebeling, Lara, et al.
Publicado: (2014)

Defining Core Competencies for Epidemiologists in Academic Settings to Tackle Tomorrow’s Health Research Challenges: A Structured, Multinational Effort
por: Abraham, Alison, et al.
Publicado: (2020)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Roflumilast in COPD: a Brazilian perspective
por: Stirbulov, Roberto, et al.
Publicado: (2015)

Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis
por: Yuan, Lianfang, et al.
Publicado: (2016)

Validity and reproducibility of a physical activity questionnaire for older adults: questionnaire versus accelerometer for assessing physical activity in older adults
por: Siebeling, Lara, et al.
Publicado: (2012)

Vulnerable COPD patients with comorbidities: the role of roflumilast
por: Lipari, Melissa, et al.
Publicado: (2014)

Efficacy and Safety of Roflumilast in Korean Patients with COPD
por: Lee, Jae Seung, et al.
Publicado: (2016)

Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review
por: Puhan, Milo A, et al.
Publicado: (2008)

A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms
por: Chiantera, Vito, et al.
Publicado: (2023)

Ethical Priority Setting for Successful Publishing by Iranian Scientists
por: Didari, Tina, et al.
Publicado: (2018)

ICE COLD ERIC – International collaborative effort on chronic obstructive lung disease: exacerbation risk index cohorts – Study protocol for an international COPD cohort study
por: Siebeling, Lara, et al.
Publicado: (2009)

New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011)

Roflumilast: a review of its use in the treatment of COPD
por: Wedzicha, Jadwiga A, et al.
Publicado: (2016)

Does roflumilast induce phagocytic activity in COPD patients?
por: Ghosh, Baishakhi, et al.
Publicado: (2015)

Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap
por: Zhang, Xiaoli, et al.
Publicado: (2018)

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
por: Puhan, Milo A, et al.
Publicado: (2009)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Discussing study limitations in reports of biomedical studies- the need for more transparency
por: Puhan, Milo A, et al.
Publicado: (2012)

Validation of prediction models based on lasso regression with multiply imputed data
por: Musoro, Jammbe Z, et al.
Publicado: (2014)

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Benefits and potential harms of COVID‐19 vaccination during pregnancy: evidence summary for patient counseling
por: Kalafat, E., et al.
Publicado: (2021)

Benefits, harms and evidence – reflections from UK primary healthcare
por: McCartney, Margaret
Publicado: (2017)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data
por: Spanu, Alessandra, et al.
Publicado: (2022)

Towards a Link between Quantitative and Qualitative Sciences to Understand Social Systems Using the Example of Informal Settlements
por: Friesen, John
Publicado: (2023)

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
por: Boswell-Smith, Victoria, et al.
Publicado: (2007)

Glucocorticoid Receptor α Mediates Roflumilast’s Ability to Restore Dexamethasone Sensitivity in COPD
por: Reddy, Aravind T, et al.
Publicado: (2020)

Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022)

The effect of two lottery-style incentives on response rates to postal questionnaires in a prospective cohort study in preschool children at high risk of asthma: a randomized trial
por: van der Mark, Lonneke B, et al.
Publicado: (2012)

UNOS policy change benefits high‐priority patients without harming those at low priority
por: Wolfson, Aaron M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p0r2pk063gpr12chkqblsc47vu